Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

VANDA Aktie

 >VANDA Aktienkurs 
4.5 EUR    -2.3%    (TradegateBSX)
Ask: 4.574 EUR / 490 Stück
Bid: 4.476 EUR / 500 Stück
Tagesumsatz: 530 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
VANDA Aktie über LYNX handeln
>VANDA Performance
1 Woche: -0,4%
1 Monat: -3,5%
3 Monate: -15,3%
6 Monate: -10,0%
1 Jahr: +16,6%
laufendes Jahr: -27,4%
>VANDA Aktie
Name:  VANDA PHARMACEUTICALS
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US9216591084 / A0JJT3
Symbol/ Ticker:  VM4 (Frankfurt) / VNDA (NASDAQ)
Kürzel:  FRA:VM4, ETR:VM4, VM4:GR, NASDAQ:VNDA
Index:  -
Profil:  Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of therapies addressing high unmet medical needs in areas such as sleep-wake disorders, psychiatric and neurologic conditions, motion sickness,..
>Volltext..
Marktkapitalisierung:  278.51 Mio. EUR
Unternehmenswert:  149.55 Mio. EUR
Umsatz:  184.7 Mio. EUR
EBITDA:  -146 Mio. EUR
Nettogewinn:  -235.32 Mio. EUR
Gewinn je Aktie:  -3.96 EUR
Schulden:  19.55 Mio. EUR
Liquide Mittel:  47.93 Mio. EUR
Operativer Cashflow:  -121.86 Mio. EUR
Bargeldquote:  1.04
Umsatzwachstum:  9.36%
Gewinnwachstum:  -323.53%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel -
Suchwörter:  VANDA
Letzte Datenerhebung:  23.08.26
>VANDA Kennzahlen
Aktien/ Unternehmen:
Aktien: 60.46 Mio. St.
Frei handelbar: 94.57%
Rückkaufquote: -
Mitarbeiter: 533
Umsatz/Mitarb.: 0.35 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 127.87%
Bewertung:
KGV: -
KGV lG: -
KUV: 1.51
KBV: 1.45
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: 89.32%
Gewinnmarge: -127.41%
Operative Marge: -86.07%
Managementeffizenz:
Gesamtkaprendite: -53%
Eigenkaprendite: -77.81%
>VANDA Peer Group
 
22.08.26 - 21:24
NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C. (PR Newswire)
 
WASHINGTON, Aug. 22, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the NEREUS™ branded No. 47 entry from Rahal Letterman Lanigan Racing, driven by Mick Schumacher, is set to compete this weekend in the inaugural Freedom 250 Grand Prix of Washington, D.......
13.08.26 - 01:24
Vanda (VNDA) Q2 2026 Earnings Call Transcript (Fool)
 
Fanapt surges 23% as Vanda expands psychiatry franchise amid pipeline progress....
06.08.26 - 01:00
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
 
Vanda (VNDA) delivered earnings and revenue surprises of -103.92% and -19.35%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?...
05.08.26 - 23:36
Vanda verfehlt Q2-Prognosen bei steigenden Verlusten (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
05.08.26 - 22:09
Vanda Pharmaceuticals GAAP EPS of -$1.04 misses by $0.45, revenue of $50.53M misses by $11.39M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
05.08.26 - 22:03
Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results (PR Newswire)
 
Fanapt® Q2 2026 net product sales increased 23% to $36.0 million; total prescriptions increased 31% Full-year 2026 total revenue guidance of $240-$290 million Cash totaled $170.0 million as of June 30, 2026; expected to fund operations through at least the end of 2027 BYSANTI™......
29.07.26 - 22:33
Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026 (PR Newswire)
 
Conference Call and Webcast to Follow WASHINGTON, July 29, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2026 on Wednesday, August 5, 2026, after the market closes. Vanda will host a conference call at......
29.07.26 - 19:42
Individual investors are dumping stocks at the fastest pace since the COVID crash (MarketWatch)
 
Individual investors just recorded “their largest net selling of single stocks since the COVID crash,” according to Vanda Research....
29.07.26 - 19:15
Retail investors sold the most single stocks since COVID-19 – Vanda Research (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
16.07.26 - 22:33
Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe (PR Newswire)
 
WASHINGTON, July 16, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Committee for Orphan Medicinal Products at the European Medicines Agency (EMA) has adopted a positive opinion recommending orphan drug designation for imsidolimab, the......
15.07.26 - 22:36
NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment (PR Newswire)
 
WASHINGTON, July 15, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUS™ (tradipitant), the first new prescription medication approved for prevention of vomiting induced by motion in 47 years, will sponsor the No. 47 entry in the NTT IndyCar......
10.07.26 - 22:33
Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit (PR Newswire)
 
WASHINGTON, July 10, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in a fireside chat at the B. Riley Securities Mind, Muscle & Vision Summit in Boston, Massachusetts on Thursday, July 16, 2026. About Vanda......
09.07.26 - 15:54
‘Retail investors are not buying the broad market, they’re buying stories’ – Vanda Research (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
08.07.26 - 12:00
FDA grants rare paediatric designation to Vanda′s CMT2S therapy (PBR)
 
The FDA's Office of Orphan Products Development and Office of Pediatric Therapeutics granted this status to the therapy. CMT2S is a rare, inherited neurological condition that progressively causes The post FDA grants rare paediatric designation to Vanda's CMT2S therapy appeared first on Pharmaceutical Business review....
07.07.26 - 22:33
Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S (PR Newswire)
 
WASHINGTON, July 7, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to VCA-894A, Vanda's investigational antisense oligonucleotide therapy for the......
17.06.26 - 21:18
SpaceX Has ‘All the Characteristics’ of a Mag 7 Stock, Top Strategist Says After Record IPO Debut (24/7 Wall St.)
 
Vanda Research's Viraj Patel walked CNBC viewers through one of the strangest sessions of the year on June 16, with a direct message: Retail investors sold the rest of the market to fund a single bet on SpaceX (NASDAQ:SPCX). “SpaceX saw the largest day of retail net buying for any IPO debut in recent history,” ... SpaceX Has 'All the Characteristics' of a Mag 7 Stock, Top Strategist Says After Record IPO Debut...
16.06.26 - 04:03
SpaceX Erupts In After Hours Trading, Hits $3 Trillion Market Cap, Surpassing Microsoft (ZeroHedge)
 
SpaceX Erupts In After Hours Trading, Hits $3 Trillion Market Cap, Surpassing Microsoft Update (9:00pm): just a few minutes after the initial post, the squeeze is accelerating and SPCX hit just shy of $230, or $3 trillion in market cap, surpassing MSFT in value. And what is even crazier, tomorrow SPCX options start trading, which means one good, solid gamma squeeze could send this stock to $400, surpassing NVDA as the world's biggest company in the process. Earlier: After a relatively calm first day of trading, the gamma squeeze crew has finally sniffed out that SpaceX's float makes it a perfect candidate for an OTM-call option driven meltup, and the stock soared ~20% today, adding over $400 billion in market in the regular session. Commenting on the move, Vanda Track earlier noted that SpaceX topped the leaderboard as the most bought stock by retail investors for a second consecutive session, with net buying potentially set to clear $100mn for the second day in a row. On a net basis, retail...
15.06.26 - 19:24
Mag 7 is no more, meet the FAB 10: Retail investors buy SpaceX in record numbers for their new portfolio plan (CNBC)
 
Single-stock retail buying was $117 million for SpaceX on its first day of trading, amounting to 56% of all retail purchases, Vanda Research found....
12.06.26 - 15:01
KI-Aktien raus, SpaceX rein? Privatanleger bereiten sich offenbar auf Mega-IPOs vor (Business Insider DE)
 
Privatanleger verkaufen laut Vanda Research zuletzt KI-Favoriten und bauen Cash auf. Grund könnte der bevorstehende Börsengang von SpaceX sein....
10.06.26 - 22:06
Equity positioning sees sharpest unwind in 15 years as AI trade cracks - Vanda (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Kein Mensch ist reich genug, um sich die eigene Vergangenheit zurückkaufen zu können. - Oscar Wilde
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!